tbuckley/cabot-search huggingface dataset:
Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction
Authors: Boback Ziaeian, Paul A. Heidenreich, Haolin Xu, Adam D. DeVore, Roland A. Matsouaka, Adrian F. Hernandez, Deepak L. Bhatt, Clyde W. Yancy, Gregg C. Fonarow
Journal: JACC Heart Failure (2017)
An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease
Authors: Paul J. Martin, Barry E. Storer, Yoshihiro Inamoto, Mary E. D. Flowers, Paul A. Carpenter, Joseph Pidala, Jeanne Palmer, Mukta Arora, Madan Jagasia, Sally Arai, Corey S. Cutler, Stephanie J. Lee
Journal: Blood (2017)
Abstract A14: Proteomic analysis of paired malignant and non-malignant tissues from patients with NSCLC adenocarcinoma identified changes in translation initiation factors potentially important in oncogenesis
Authors: Suzanne Miyamoto, Johannes F. Fahrmann, Dmitry Grapov, Brett Phinney, Harvey Pass
Journal: Cancer Research (2017)

Abstract An important aspect of the control of mRNA translation into protein in mammalian cells is the initiation process, which involves the activities of multiple eukaryotic translation initiation factors or eIFs. Genetic analyses of eIFs in yeast (S. cerevisiae) have defined the eIFs necessary for the basic translation of mRNAs into proteins, but additional subunits found in mammalian cells have not been as well defined in normal cells so how the activities and functions of eIFs may be dysregulated in cancers such as lung cancer are still being determined. Lung cancer causes the highest cancer mortality in men and women in the United States. Lung cancer, mostly non-small cell (NSCLC) adenocarcinoma is responsible for about 13% of all new cancer cases and 26% of all cancer deaths. We undertook a proteomic analysis of lung cancer by analyzing 39 pairs of malignant and non-malignant lung tissues obtained from patients with early stage NSCLC adenocarcinoma using trypsin digestion and tandem MS/MS. Examination of eIFs in these tissues showed significant proteomic differences with significant increases in eIFs, especially in eIF2A, eIF2B, 1 alpha, and eIF2B, 5 episilon (p-values &amp;lt; 0.05). Smaller, but significant increased fold changes were also observed in eIF3B, eIF3G, eIF3J, eIF4G1, eIF4E eIF4A1 and eIF4H. Increased protein levels of EIF2AK2, the interferon induced eIF2A protein kinase was also detected. The eIF2alpha exchange rate may be an important aspect of tumorigenesis in lung cancer tissues with the increased exchange of GTP for GDP in eIF2A, hence the large increases in eIF2B subunits. Increases in eIF3 subunits, especially eIF3j, as well as increases in eIF4E and eIF4G1 correspond to increased protein synthesis rates and cellular proliferation. These early results need further investigation and related functional analysis to determine if the changes in eIFs correspond to important activities in the tumor cells or surrounding microenvironment and have mechanistic consequences in the growth and progression of lung cancer tumors. Citation Format: Suzanne Miyamoto, Johannes F. Fahrmann, Dmitry Grapov, Brett Phinney, Harvey Pass. Proteomic analysis of paired malignant and non-malignant tissues from patients with NSCLC adenocarcinoma identified changes in translation initiation factors potentially important in oncogenesis. [abstract]. In: Proceedings of the AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; 2016 Oct 27-30; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2017;77(6 Suppl):Abstract nr A14.
Determinants of long term survival and recurrence patterns after radiofrequency ablation for hepatocellular carcinoma developed on cirrhosis
Authors: M. Allaire, S. Rekik, A. Mumana, E. Guyot, G. Nkontchou, V. Bourcier, V. Grando, M. Ziol, P. Nahon, N. Ganne-Carrié, O. Seror, J.-C. Nault
Journal: Journal of Hepatology (2017)
Relationship between HBsAg, HBV DNA, covalently closed circular DNA and fibrosis stage in chronic HBV (HBeAg-negative) patients
Authors: I. Gabdrakhmanov, K. Zhdanov, K. Kozlov, A. Semenov, V. Sukachev, J. Ostankova, A. Gvozdetskiy, S. Zhabrov, E. Kudelka
Journal: Journal of Hepatology (2017)
Measurements of Prothrombin Fragment 1.2 In Urine and Blood to Assess Hypercoagulability In Preeclampsia
Authors: Anita Sylvest Andersen, Anna-Marie Münster, Thomas Bergholt, Isabelle Deltour, Merete Bak Bertelsen, Jawed Fareed, Michael Rud Lassen
Journal: Blood (2010)
Progression patterns at RECIST PD during EGFR-TKIs in advanced NSCLC patients harboring <i>EGFR</i> mutation.
Authors: Tatsuya Yoshida, Kiyotaka Yoh, Koichi Goto, Shingo Matsumoto, Shigeki Umemura, Seiji Niho, Hironobu Ohmatsu, Yuichiro Ohe
Journal: Journal of Clinical Oncology (2013)

8078 Background: The progression patterns at RECIST PD during EGFR-TKIs in advanced NSCLC patients harboring EGFR mutation are clinically heterogeneous. The aim of this study is to evaluate progression patterns at RECIST PD during EGFR-TKIs in advanced NSCLC patients harboring EGFR mutation. Methods: From 2008 to 2012, 160 consecutive patients with advanced NSCLC harboring EGFR mutation were treated with EGFR-TKIs (erlotinib or gefitinib) at our institution. Among these patients, 104 patients who experienced RECIST PD assessed by radiologic findings were retrospectively evaluated for initial response on EGFR-TKIs, progression sites, focus of progression (solitary lesion or multiple lesions), patients status at RECIST PD, and post progression survival (PPS) from RECIST PD. Results: In 104 patients, 96 (92%) patients had EGFR major mutation (Exon 19 deletion and L858R), and 49 (47%) received EGFR-TKIs as first-line. The overall response rate and median progression free survival on EGFR-TKIs was 69 % and 8.2 months. At the time of RECIST PD, 44 (42%) patients had symptomatic, and 60 (58%) had asymptomatic. The progression sites were isolated CNS in 17 (16%) patients, isolated bone in 7 (7%), isolated pulmonary in 13 (12%), systemic in 67 (65%) patients. In the focus of progression, 24 (23%) patients have solitary lesion, and 80 (77%) have multiple lesions. After RECIST PD, 40 (38%) patients continued EGFR-TKIs, 25 (24%) were switched to cytotoxic agents, and 39 (38%) had best supportive care. 10 (10%) patients received local radiotherapy for isolated progression site (brain 6; bone 3; lung 1) and 8 of these patients continued EGFR-TKIs. The median PPS from RECIST PD was 10.6 months. Multivariate analysis identified that asymptomatic or solitary progression lesion at RECIST PD were associated with significantly longer PPS (asymptomatic: HR 0.34, 95% CI 0.19-0.58, P&lt;0.001; solitary progression lesion: HR 0.39, 95% CI 0.16-83, P=0.013). Conclusions: The progression patterns at RECIST PD during EGFR-TKIs in advanced NSCLC patients harboring EGFR mutation have widely diversity. Further investigation for association between progression patterns at RECIST PD and clinical outcome after RECIST PD is warranted.
Intravenous Iron
Authors: Michael Auerbach, George M. Rodgers
Journal: New England Journal of Medicine (2007)

To the Editor: Before iron was used as an adjunct to erythropoietic stimulatory therapy in patients undergoing hemodialysis, parenteral iron was considered to be dangerous.High-molecularweight iron dextran (Imferon [Fisons], which is no longer manufactured) was the only product available and was associated with anaphylaxis.Nonetheless, marked improvements in hemoglobin responsiveness 1 resulted in the extensive use of high-molecular-weight iron dextran in nephrology.In the mid-1990s, two events changed the prescribing practices of nephrologists.First, high-molecular-weight iron dextran was removed from the market, and subsequently, low-molecular-weight iron dextran (InFed [Watson]) was released.Low-molecular-weight iron dextran was the standard of care for patients with anemia from hemodialysis. 1 Shortly thereafter, another high-molecular-weight iron dextran product (DexFerrum [American Regent]) was released for clinical use.Two new compounds, ferric gluconate (Ferrlecit [Watson]) and iron sucrose (Venofer [American Regent]), were introduced in the late 1990s.These new products were associated with lower rates of serious adverse events than were the previously released products. 2When reported serious adverse events were stratified according to the product, 3 virtually all events were due to high-molecular-weight iron dextran; the incidence of acute reactions with each of the other three products, including low-molecular-weight iron dextran, was approximately 1 in 200,000.In September 1998, the distribution of low-
Implementation of Rapid Treatment and Interfacility Transport for Patients With Suspected Stroke by Large-Vessel Occlusion
Authors: Kori Sauser Zachrison, Lee H. Schwamm
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
RELATION OF AMERICAN DIETARY TO DEGENERATIVE DISEASE
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevalence of fatty liver and fibrosis in patients with type 2 diabetes mellitus and previously undetected liver disease as assessed by transient elastography and ultrasound
Authors: I. Grgurevic, T. Bokun, S. Mustapic, V. Matic, D. Rahelic, T. Matic, N. Salkic, V. Bozikov, M. Banic, M. Kujundzic
Journal: Journal of Hepatology (2017)
A prospective, randomized, multicenter and phase 3b study to evaluate the efficacy of terlipressin and albumin in cirrhotic patients with ascites and acute kidney injury in the range of serum creatinine between 1.5 mg and 2.5 mg/dl: interim analysis
Authors: J.H. Sohn, Y.K. Cho, J.H. Kim, Y.K. Jung, S.H. Um, S.B. Ahn, C.H. Lee, J.Y. Jang, Y.S. Kim, H.S. Kim, D.J. Kim, M.Y. Kim, D.W. Jun
Journal: Journal of Hepatology (2017)
Topical betamethasone 17-valerate is an anticorticosteroid in the rat.
Authors: JOHN M. YOUNG, BONNIE M. WAGNER, ROBERT A. FISK
Journal: British Journal of Dermatology (1978)

In the oxazolone-induced delayed hypersensitivity inflammation in the rat ear, betamethasone 17-valerate, in contrast to other topical corticosteroids, is incapable of suppressing oedema. When given in combination with triamcinolone acetonide, betamethasone 17-valerate competitively antagonizes the anti-inflammatory action of the active steroid. When tested in the mouse, betamethasone 17-valerate behaved as an anti-inflammatory agent 15 and 80 times as potent as betamethasone and hydrocortisone respectively. In an in vivo lymphocyte culture system in which preincubation with corticosteroids prevents subsequent phytohaemagglutinin induced DNA synthesis, betamethasone 17-valerate was less active than even hydrocortisone when rat lymph node cells were used, but with human cell preparations it was more potent than either hydrocortisone or betamethasone. Betamethasone 17-valerate behaves uniquely in the rat as an anticorticosteroid; in mouse and in man the compound behaves as a normal corticosteroid.
Physical chitosan microhydrogels as scaffolds for spinal cord injury restoration and axon regeneration
Authors: Jamila Chedly, Sylvia Soares, Alexandra Montembault, Ysander von Boxberg, Michèle Veron-Ravaille, Christine Mouffle, Marie-Noelle Benassy, Jacques Taxi, Laurent David, Fatiha Nothias
Journal: Biomaterials (2017)
PTU-106 Successful Pregnancies With Thiopurine-allopurinol Co-therapy For Inflammatory Bowel Disease: Abstract PTU-106 Table 1
Authors: M Sheikh, C Nelson-Piercy, J Stenner, G Mackenzie, J Duley, T Florin, A Ansari
Journal: Gut (2014)

<h3>Introduction</h3> Combination of low dose thiopurine with allopurinol can improve the clinical efficacy and bypass some of the adverse reactions of thiopurine monotherapy. Thiopurines can be used safely during pregnancy but there is scarce data regarding allopurinol. We report twelve cases of safe use of thiopurine and allopurinol co-therapy to manage IBD during pregnancy. <h3>Methods</h3> Patients were retrospectively identified at two hospitals in the UK and in Australia, using our local IBD databases. All pregnancies of co-therapy patients were included. TPMT activity and pre-pregnancy weight were used to calculate thiopurine dosing. Data regarding pregnancy and fetal outcomes were collected from patient notes. <h3>Results</h3> Eleven females on co-therapy became pregnant, totalling twelve pregnancies with eight live births (Table 1) and four ongoing pregnancies. There were no reported terminations, miscarriages or spontaneous pre-term deliveries (&lt;37 weeks). Four patients gave birth by spontaneous vaginal delivery (SVD); four by Caesarean section (C-section). There were no low birth weight (&lt;2.5kg) babies. The APGAR scores of all babies were normal and no congenital malformations were identified either on fetal ultrasound scans or on neonate checks. The median duration of follow-up of babies was 6.5 months with no indication of morbidity. <h3>Conclusion</h3> All twelve cases were treated successfully with co-therapy without any adverse pregnancy related events or adverse fetal outcomes. Intrauterine exposure of the fetus to thiopurine metabolites is not greater with combination therapy compared with thiopurine monotherapy. There are only two reports of congenital malformations with maternal allopurinol use. The case for an association based on two cases is weak, moreover a negative publication bias with respects to successful maternal allopurinal use is suspected. Our study provides support for clinicians and patients wishing to continue thiopurine-allopurinol co-therapy during pregnancy. <h3>Disclosure of Interest</h3> None Declared.
IL-22BP dictates characteristics of Peyer’s patch follicle-associated epithelium for antigen uptake
Authors: Toshi Jinnohara, Takashi Kanaya, Koji Hase, Sayuri Sakakibara, Tamotsu Kato, Naoko Tachibana, Takaharu Sasaki, Yusuke Hashimoto, Toshiro Sato, Hiroshi Watarai, Jun Kunisawa, Naoko Shibata, Ifor R. Williams, Hiroshi Kiyono, Hiroshi Ohno
Journal: The Journal of Experimental Medicine (2017)

Interleukin-22 (IL-22) acts protectively and harmfully on intestinal tissue depending on the situation; therefore, IL-22 signaling needs to be tightly regulated. IL-22 binding protein (IL-22BP) binds IL-22 to inhibit IL-22 signaling. It is expressed in intestinal and lymphoid tissues, although its precise distribution and roles have remained unclear. In this study, we show that IL-22BP is highly expressed by CD11b+CD8α− dendritic cells in the subepithelial dome region of Peyer’s patches (PPs). We found that IL-22BP blocks IL-22 signaling in the follicle-associated epithelium (FAE) covering PPs, indicating that IL-22BP plays a role in regulating the characteristics of the FAE. As expected, FAE of IL-22BP–deficient (Il22ra2−/−) mice exhibited altered properties such as the enhanced expression of mucus and antimicrobial proteins as well as prominent fucosylation, which are normally suppressed in FAE. Additionally, Il22ra2−/− mice exhibited the decreased uptake of bacterial antigens into PPs without affecting M cell function. Our present study thus demonstrates that IL-22BP promotes bacterial uptake into PPs by influencing FAE gene expression and function.
Antacid use and subclinical interstitial lung disease: the MESA study
Authors: Michaela D. Restivo, Anna Podolanczuk, Steven M. Kawut, Ganesh Raghu, Peter Leary, R. Graham Barr, David J. Lederer
Journal: European Respiratory Journal (2017)

Idiopathic pulmonary fibrosis (IPF), a prevalent fibrotic idiopathic interstitial lung disease (ILD), is thought to result from recurrent subclinical alveolar epithelial cell (AEC) injury followed by abnormal repair and fibrogenesis [1]. Gastro-oesophageal reflux disease (GORD) has been implicated in AEC injury in IPF [2]. GORD is a prevalent comorbidity in adults with IPF [3], and the gastric enzyme pepsin has been identified in bronchoalveolar lavage fluid of patients with acute IPF exacerbations [4], suggesting a role of micro-aspiration in disease progression. Proton pump inhibitor use is associated with a reduction in subclinical interstitial lung disease <http://ow.ly/dbFN30aoRPf>
Co-inheritance of two rare genodermatoses (Papillon Lefevre syndrome and Oculocutaneous Albinism Type 1) in two families
Authors: C. Hewitt, C.L. Wu, F.N. Hattab, W. Amin, K.A. Ghaffar, C. Toomes, P. Sloan, A.P. Read, Jacqueline James, N.S. Thakker
Journal: British Journal of Dermatology (2004)
Measles outbreak in Somali American community follows anti-vaccine talks
Authors: Owen Dyer
Journal: BMJ (2017)

The US state of Minnesota is facing its largest measles outbreak in nearly 30 years, with 58 cases reported over the past month, including 14 admissions. All but three of the cases occurred in unvaccinated children under 10, mostly in the 32 000 strong Somali American community around Minneapolis.

The community’s child vaccination rates for measles, mumps, and rubella (MMR) have plummeted from 92% in 2004 to 42% in 2014, amid fears that its children have unusually high rates of autism.

These concerns have attracted the attention of anti-vaccine activists, including the disgraced former UK gastroenterologist Andrew Wakefield, who held at least two meetings with Somali community groups in Minnesota in 2010-11, when their vaccination uptake was falling quickly.

Efforts by anti-vaccine activists continued even during the outbreak. On 30 April, Mark Blaxill, founder of the anti-vaccine Canary Party, addressed a crowd of roughly 90 parents …
Attitudes of Terminally Ill Cancer Patients About Euthanasia and Assisted Suicide: Predominance of Psychosocial Determinants and Beliefs Over Symptom Distress and Subsequent Survival
Authors: Maria E. Suarez-Almazor, Catherine Newman, John Hanson, Eduardo Bruera
Journal: Journal of Clinical Oncology (2002)

PURPOSE: Although euthanasia and physician-assisted suicide (PAS) are controversial issues, the views of those most affected, terminal patients, are seldom explored. Our objective was to assess whether the attitudes about euthanasia/PAS of terminally ill cancer patients were determined by their symptomatic distress. PATIENTS AND METHODS: We conducted a survey of 100 patients with terminal cancer. Statements related to the legalization of euthanasia/PAS were scored using Likert scales. We also asked patients how often they had considered ending their lives. Their responses were analyzed in relation to disease characteristics, including an assessment of symptomatic severity, sociodemographic features, general beliefs about the suffering of cancer patients, and survival. RESULTS: Most patients (69%) supported euthanasia or PAS for one or more situations. The association between these attitudes and symptoms was weak, consistent in univariate analysis only for shortness of breath. No significant associations were observed with pain, nausea, well-being, loss of appetite, depression, or subsequent survival. Agreement with euthanasia was significantly related to male sex, lack of religious beliefs, and general beliefs about the suffering of cancer patients and their families. In multivariate analysis, the only characteristics that remained statistically associated with support were the strength of religious beliefs and the perception that patients with cancer are a heavy burden on their families. Frequency of suicidal ideation was associated with poor well-being, depression, anxiety, and shortness of breath, but not with other somatic symptoms such as pain, nausea, and loss of appetite. CONCLUSION: Symptom intensity had limited impact on the attitudes about euthanasia of terminally ill cancer patients. Our findings suggest that patient views are primarily determined by psychosocial traits and beliefs, as opposed to disease severity or symptomatic distress.
Pulmonary Langerhans'-Cell Histiocytosis
Authors: Robert Vassallo, Jay H. Ryu, Thomas V. Colby, Thomas Hartman, Andrew H. Limper
Journal: New England Journal of Medicine (2000)

Pulmonary Langerhans'-cell histiocytosis forms part of a spectrum of diseases characterized by monoclonal proliferation and infiltration of organs by Langerhans' cells (Table 1).1 Several organ systems may be involved in Langerhans'-cell histiocytosis, including the lungs, bone, skin, pituitary gland, liver, lymph nodes, and thyroid.2 Lung involvement may occur either in isolation or as part of a multiorgan disease (Table 1). The term "pulmonary Langerhans'-cell histiocytosis" is used to refer to disease in adults that affects the lung, either in isolation or in addition to other organ systems.Localized forms of Langerhans'-cell histiocytosis have previously been referred to as eosinophilic granuloma, . . .